Older patients ‘are being overlooked’ for cancer trials

Industry-funded trials appear to be the worst offenders, say researchers
Reuters Health

Patients selected to participate in studies of cancer drugs tend to be younger than those with the disease in the general population, according to a US study.

To measure the age disparity, researchers from the University of Texas MD Anderson Cancer Centre, in Houston, analysed information from 302 cancer clinical trials listed on the ClinicalTrials.gov website between 1994 and 2015, including more than 262,000 patients.